Mediterr J Rheumatol 2015; 26(2): 44-53
Clinical use of subcutaneous Abatacept in the treatment of rheumatoid arthritis
Authors Information
Rheumatology Unit, First Department of Propedeutic and Internal Medicine, Athens University Medical School
  1. Smolen J, Landew? R, Breedveld F, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2013;73:492–509.
  2. Conti F, Ceccarelli F, Massaro L, Cipriano E, Di Franco M, Alessandri C,  et al. Biological therapies in rheumatic diseases. Clin Ter 2013; 164: e413–28.
  3. Corbo M, Valencia X, Raymond R, et al. Subcutaneous administration of abatacept in patients with rheumatoid arthritis: Pharmacokinetics, safety and immunogenicity [EULAR abstract SAT0101]. Ann Rheum Dis  2009; 68(Suppl. 3): 574
  4. Genovese M, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, et al. Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 2011; 63: 2854–64.
  5. Nash P, Nayiager S, Genovese M, Kivitz AJ, Oelke K, Ludivico C, et al. Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel?Arm, Open?Label Study. Arthritis Care Res 2013; 65: 718–28.
  6. Kaine J, Gladstein G, Strusberg I, Robles M, Louw I, Gujrathi S, et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study). Ann Rheum Dis 2012; 71: 38–44.
  7. Keystone E, Kremer J, Russell A, Box J, Abud-Mendoza C, Elizondo MG, et al. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann Rheum Dis 2012; 71: 857–61.
  8. Weinblatt M, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, et al. Head?to?head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study. Arthritis & Rheumatism 2013; 65: 28–38.
  9. Emery P, Burmester G, Bykerk V, Combe BG, Furst DE, Barr? E, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 2015; 74: 19-26.
  10. Genovese M, Tena C, Covarrubias A, Genovese MC, Tena CP, Covarrubias A, et al. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial. J Rheumatol. 2014; 41: 629-39.
  11. Iwahashi M, Inoue H, Matsubara T, Tanaka T, Amano K, Kanamono T, et al. Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study. Mod Rheumatol 2014; 24: 885–91.
  12. Amano K, Matsubara T, Tanaka T, Inoue H, Iwahashi M, Kanamono T, et al. Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders. Mod Rheumatol 2015 ; 25: 665-71.
  13. Reggia R, Franceschini F, Tincani A, Cavazzana I. Switching from Intravenous to Subcutaneous  Formulation of Abatacept: A Single-center Italian Experience on Efficacy and Safety. J Rheumatol. 2015; 42: 193–5
  14. Alten R, Kaine J, Keystone E, Nash P, Delaet I, Genovese M. Long?Term Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: Integrated Analysis of Clinical Trial Data Representing More Than Four Years of Treatment. Arthr Rheumatol 2014; 66: 1987–97.
  15. Weinblatt ME, Moreland LW, Westhovens R, Cohen RB, Kelly SM, Khan N, et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J Rheumatol 2013; 40: 787–97.
  16. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013; 381: 1541–50.
  17. Favalli EG, Bugatti S, Biggioggero M, Caporali R. Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs. Biomed Res Int 2014; 2014: 831603.
  18. Scarpato S, Antivalle M, Favalli EG, Nacci F, Frigelli S, Bartoli F, et al. Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford) 2010; 49: 289–94.